Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

UroGen Pharma (URGN) Cost of Revenue (2018 - 2025)

UroGen Pharma's Cost of Revenue history spans 7 years, with the latest figure at $3.3 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 33.1% year-over-year to $3.3 million; the TTM value through Dec 2025 reached $12.4 million, up 40.15%, while the annual FY2025 figure was $12.4 million, 40.15% up from the prior year.
  • Cost of Revenue reached $3.3 million in Q4 2025 per URGN's latest filing, roughly flat from $3.3 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $3.6 million in Q2 2025 to a low of $897000.0 in Q1 2021.
  • Average Cost of Revenue over 5 years is $2.2 million, with a median of $2.3 million recorded in 2022.
  • Peak YoY movement for Cost of Revenue: soared 2872.92% in 2021, then dropped 23.71% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at $1.6 million in 2021, then soared by 42.42% to $2.3 million in 2022, then rose by 1.02% to $2.3 million in 2023, then grew by 8.09% to $2.5 million in 2024, then soared by 33.1% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Cost of Revenue are $3.3 million (Q4 2025), $3.3 million (Q3 2025), and $3.6 million (Q2 2025).